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Abstract
Background: The NHS Bowel Scope Screening (BSS) programme offers men and women aged 55 years a once-
only flexible sigmoidoscopy (FS), a test that can help reduce colorectal cancer (CRC) incidence and mortality.
However, the benefits of BSS are contingent on uptake. This National Institute for Health Research-funded single-
stage phase II trial will test the feasibility of using patient navigation (PN), an intervention that offers support to
patients to overcome barriers to healthcare, to increase BSS uptake within a socially deprived area of England.
Methods/design: All individuals invited for BSS at South Tyneside NHS Foundation Trust during the 6-month
recruitment period will be invited to take part in the study. Consenting participants will be randomised to receive
PN or usual care in a 2:1 ratio. PN involves non-attenders receiving a phone call from a Specialist Screening
Practitioner (SSP) who will elicit reasons for non-attendance and offer educational, practical, and emotional support
as needed. If requested by the patient, another appointment for BSS will then be arranged. We anticipate 30 % of
participants will be non-attenders. Using A’Hern single-stage design, with 20 % significance level and 80 % power,
at least 35 participants who receive PN need to subsequently attend for PN to be considered worthy of further
investigation in a definitive trial. The primary outcome measure will be the number of participants in the PN group
who re-book and attend their BSS appointment. A qualitative analysis of the PN transcripts, and interviews with the
SSPs, will also be conducted, alongside a quantitative analysis of completed patient-reported experience
questionnaires. An economic analysis will calculate the costs of delivering PN.
Discussion: This feasibility study will be instrumental in deciding whether to conduct the first definitive trial of PN
in BSS in England. If PN is subsequently shown to be cost-effective at increasing uptake of BSS, NHS policies could
be modified to implement PN as a standard service. The results will be disseminated in peer-reviewed journals and
at scientific conferences.
Trial registration: International Standard Randomised Controlled Trial Number, ISRCTN13314752
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Background
Colorectal cancer (CRC) is the fourth most common
cancer and the second leading cause of cancer death in
England [1]. CRC screening can help detect cancer early,
when it is more easily treated, subsequently helping to
reduce CRC mortality rates [2, 3]. In England, the National
Health Service (NHS) runs an organised population-based
CRC screening programme (Bowel Cancer Screening
Programme, BCSP) which offers biennial screening via
guaiac-based faecal occult blood testing (gFOBt) to men
and women aged 60–74. In March 2013, the BCSP add-
itionally started the national roll-out of the ‘Bowel Scope
Screening (BSS) Programme’, which offers men and women
a single flexible sigmoidoscopy (FS) examination at age 55.
The UK FS trial has shown that a single FS examination,
with its capacity to remove any pre-malignant growths,
reduces CRC mortality by 43 % and incidence by 33 % [4].
Similar to all cancer screening programmes, the bene-
fits of BSS are largely dependent on high uptake; in the
current BCSP using gFOBt, only 54 % of people invited
to do the gFOBt return a completed kit [5]. Findings
from a meta-analysis and a pathfinder study suggest that
uptake of BSS is likely to be as low as gFOBt, undermin-
ing the potential of the programme [6, 7]. Analyses of
uptake data from the first 14 months of the BSS
programme roll-out in six pilot centres indicated uptake
to be only 43.1 % [8]. BSS participation has also been
found to be strongly socially graded, ranging from
32.7 % in the most deprived to 53.2 % in the least
deprived area quintiles, resulting in an urgent need to
develop effective interventions to promote BSS uptake,
particularly among lower SES groups.
Patient navigation (PN) involves specially trained individ-
uals giving tailored support to patients to overcome barriers
personally preventing them from optimising their health-
care along the cancer pathway. PN can take on many com-
munication formats, e.g. face-to-face or over the telephone,
and includes the delivery of clear information and practical
guidance and advice to the individual, in an emotionally
supportive context [9]. PN has been shown to increase can-
cer screening participation in the USA, including CRC
screening [10–13]. It is particularly effective among ‘hard-
to-reach’ groups but has also been effective in the general
population. A recent trial found benefits associated with
PN over-and-above providing an organised screening
programme [13]. In the UK, PN has currently only been
employed in a breast cancer screening context, with results
showing an increase in uptake among African Caribbean
women, in two socially diverse areas of London [14].
Incorporating PN within a CRC screening context in
the UK, and providing a more personal and interactive
approach to communicating information about BSS, may
circumvent many barriers to CRC screening. Evidence
from the gFOBt screening programme suggests that older
adults, particularly those with low literacy, have difficulty
in extracting what they need from the current information
materials [15–17]. There is also a lack of public awareness
of CRC as a common cancer and of the primary aim of
BSS in preventing rather than diagnosing CRC [18].
Logistical barriers to preparing for, and participating in,
hospital-based BSS appointments have also been identi-
fied. For example, difficulties have been found in compre-
hending instructions for home-administered enemas for
bowel preparation, particularly for those with low literacy,
even though it is reasonably acceptable among the public
[19, 20]. There are also some well-recognised emotional
barriers including fear of the test and cancer diagnosis and
fatalistic attitudes [21]. Helping to manage feelings and
fears associated with cancer is one of the main tasks ad-
dressed by patient navigators alongside access to care and
other logistical issues (e.g. transportation) [9, 22].
This pilot trial will test the feasibility of using a PN
intervention to increase uptake of BSS in a socially de-
prived area in the North East of England. The interven-
tion will involve Specialist Screening Practitioners (SSPs)
giving tailored support to individuals who do not attend
their appointment for BSS.
SSPs are well situated to deliver PN as they are already
highly knowledgeable about BSS and the BCSP more gener-
ally, regularly communicating with patients the risks and
benefits of screening and supporting patients through their
screening procedures (FS or follow-up colonoscopy). The
high attendance rates among those requiring follow-up in-
vestigations after gFOBt [23], and the high levels of patient
satisfaction, highlight the effective educational and pastoral
achievements of SSPs in the screening programme (Vart G,
Marshall S, Nickerson C, Rees C, Wardle J, Von Wagner C:
Patient reported experiences among patients requiring
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diagnostic follow-up in the English Bowel Cancer Screening
Programme, unpublished).
The primary objective of this study is to assess the feasi-
bility of incorporating PN for patients who do not confirm
or attend their BSS appointment. The results will inform
the design of a future large-scale randomised controlled
trial (RCT), to compare whether a PN intervention is
more effective at increasing uptake of BSS than the ‘usual
care’. The feasibility of the PN intervention will be deter-
mined by measuring the number of people who provide
their contact details (recruitment rates), the acceptability
of PN from the perspective of patients (patient-reported
experience questionnaires) and staff (exit interviews with
SSPs and the Research Nurse), and BSS uptake rates of
those navigated. The costs of delivering PN will also be
calculated, and we will plan the economic evaluation that
would accompany the subsequent RCT.
Methods/design
Design
A single-stage phase II trial will test whether PN is likely
to meet the basic level of efficacy (in this case by in-
creasing uptake), is practical and acceptable within a UK
setting and is therefore worthy of further investigation in
a large-scale RCT [24]. To enhance the opportunity to
conduct PN with individuals who do not confirm or at-
tend their appointment, while keeping SSP workload to
a minimum, a randomisation ratio of 2:1 will be used in
favour of the intervention group (vs. usual care). The
aim of the trial is not to make a direct comparison be-
tween the intervention and control groups but rather to
consider the level of uptake in the PN group, while also
assessing patients’ acceptability and willingness to be
randomised. The CONSORT diagram is shown in Fig. 1.
The design of this protocol has followed the recommen-
dations of the Standard Protocol Items: Recommendations
for Interventional Trials (SPIRIT) guidelines [25, 26]. A
full copy of the SPIRIT guidelines checklist can be found
in Additional file 1.
Recruitment and setting
Recruitment will be conducted through the South of Tyne
Screening Centre. The Screening Centre operates across
three sites with one site, South Tyneside District Hospital
(STDH), involved in this current study. Approximately, 40
people each week are invited to have BSS at STDH. All in-
dividuals invited for BSS at STDH will also be invited to
take part in this study (see Fig. 2). There are no study ex-
clusion criteria; however, only individuals who return a
study consent form with their contact details, including
telephone number(s), will be able to participate in this
study. Recruitment will occur over a 6-month period.
The intervention
The PN intervention will consist of at least one tele-
phone call that will begin with the SSP introducing
themselves and the purpose of the call. The SSP will use
open-ended and non-threatening questions to elicit rea-
sons for the patient’s non-attendance/non-confirmation
and their motivation to attend BSS in the future. If the
patient appears interested in BSS, the SSP will reiterate
its benefits and offer solutions to any identified barriers
(e.g. an earlier appointment time or assistance with the
enema). In the role of navigator, the SSP should provide
two types of support: practical/instrumental and
Invited to 
participate
(n = 960)
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Consent form 
returned
(n = 384)
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Fig. 1 CONSORT flow diagram outlining the study procedure (with estimated numbers)
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emotional/relationship [27]. The SSPs will receive train-
ing on what PN is and how it should be delivered during
this study. A manual will be developed to supplement the
training and provide a resource for SSPs. The training will
be assisted by a patient representative who will conduct
role play scenarios and provide feedback to the SSPs. The
navigator should refer to the manual for instrumental sup-
port options but use their communication and interper-
sonal skills to offer emotional support and strengthen the
relationship between the hospital and the patient.
Procedure
The Screening Centre hub, where all BSS invitations are
packed and prepared for mail out, will oversee the study
invitation process. During the recruitment period, the
hub staff will insert a study invitation envelope to the
standard BSS pre-invitation letter sent to all eligible indi-
viduals. The BSS pre-invitation letter briefly introduces
BSS and forewarns of an additional letter being sent in a
further 2 weeks, which will formally invite the individual
to attend a BSS appointment at a specific date and time
(see Fig. 2 for the BSS invitation process). The study in-
vitation envelope will contain a participant information
sheet (PIS), a consent form, a pre-paid return envelope,
and a non-participation postcard. The PIS will provide
information about the aim of the research study and de-
tailed information about the consent process, data pro-
tection and study procedure, including the telephone
number that will show on their caller display if they
were to receive a call from an SSP. It will be made clear
that the decision to participate in the study is separate
to the decision to take part in screening. Each consent
form will have a unique study ID attached to it, and hub
staff will note which study ID corresponds to each per-
son invited. To take part in the study, participants will
be asked to complete and return the consent form to the
Pre-invitation 
letter
Study Invitation:
participant information 
sheet (PIS), consent form
and non-participation 
postcard sent
Invitation letter 
(with an appointment note and an information leaflet)
2 weeks
Confirmed
appointment
4 weeks
2 weeks
Attend 
appointment
Patient 
Navigation
Reminder letter 
(with an appointment note and an information 
Confirmed 
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No confirmation
2 weeks to respond
2 weeks
No confirmation
Enema 
preparation letter 
and leaflet
Patient 
Navigation
Appointment cancelled: 
Cancellation letter sent
Do not attend their 
appointment:
DNA letter sent
2 weeks to respond
Fig. 2 Positioning of the intervention within the structure of the BSS programme
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Research Nurse (RN) at STDH in the return envelope
provided. Those not wanting to take part in the study
will be invited to indicate their reason on the non-
participation postcard and return it freepost to the
researchers.
By offering consent, participants will be agreeing to
share their contact details with the assigned RN and to
be potentially contacted by a SSP. The RN will contact
the hub staff to confirm the NHS number of those con-
senting to take part in the study, using the unique study
ID. Once the RN has the NHS numbers, they can then
use the web-based national Bowel Cancer Screening Sys-
tem (BCSS) within STDH to follow each participant
along the BSS pathway and obtain their BSS confirm-
ation and attendance status.
On receipt of each consent form, the RN will consult a
pre-generated randomisation list to determine which
study group each participant should be allocated to. Two
randomisation lists (one for each gender) will be generated
by a medical statistician, who will randomly allocate par-
ticipants to receive either PN or usual care with a ratio of
2:1 favouring the intervention. It is not possible to blind
the RN and SSPs to each participant’s study group alloca-
tion. However, the participants themselves will only know
the group they have been allocated to when they receive
either a navigation phone call or their end-of-study ques-
tionnaire (ESQ): the ESQ will be accompanied by a cover
letter thanking them for their participation and informing
them of their group allocation.
The RN will work with University College London
(UCL) researchers and SSPs and use the BCSS to docu-
ment all activities of consenting participants on a data-
base devised for this study (e.g. group assignment,
original appointment date and subsequent changes
made, attendance status, date of ESQ mail out, and date
of receipt of completed ESQ). This will allow the RN to
monitor who is eligible for PN and to obtain important
information for establishing the feasibility of the study
design and expectations for the larger RCT.
Usual care group
As per the standard BSS process (see Fig. 2), individuals
in the usual care group will receive an invitation to take
part in BSS 2 weeks after receiving the pre-invitation let-
ter (and study information envelope). The BSS invitation
letter includes details of an assigned appointment date
and time (8 weeks in advance). The letter also requests
confirmation of the appointment. If no confirmation is
received from the patient within 2 weeks of the invita-
tion going out, a reminder invitation letter is sent. If
confirmation is still not received within 2 weeks of the
reminder, a ‘cancellation’ letter is sent and there is no
further contact from the Screening Centre. If confirm-
ation is received, an enema with preparation instructions
is sent approximately 2 weeks before the appointment
date. Patients who confirm but then fail to attend their
appointment receive a ‘did not attend (DNA)’ letter.
Intervention group
Individuals in the intervention group will also follow the
above usual care process. However, if an individual
either fails to confirm or attend a confirmed appoint-
ment (‘non-attenders’), they will, in addition to the
cancellation/DNA letter, enter a navigation episode,
whereby a SSP trained in PN will make up to three
attempts to contact the individual by telephone. All call
attempts will be documented and, if contact is made, the
SSP will establish the reasons for non-attendance, offer
support and, if suitable, arrange a new appointment. The
navigation episode could involve multiple telephone
conversations and closes when a decision to arrange a
new BSS appointment, or not, is made. Participants in
the PN group will only be eligible for one navigation epi-
sode, i.e. if a further BSS appointment is made following
PN, but is not attended, only a further ‘DNA’ letter is
sent, as per standard practice: no additional navigation
call attempts will be made.
All consenting participants will be sent an ESQ, with a
freepost-return envelope, either 4 weeks following an
attended appointment or 1 week after a non-attended
appointment or final PN call (see Fig. 3). There will be
four versions of the ESQ with questions varying depend-
ing on the participant’s study group and BSS attendance
status. The aim of the ESQ is to assess participants’
knowledge of BSS and their satisfaction with their choice
to attend screening or not. The ESQ for those receiving
PN also aims to find out how participants felt about this
process (e.g. their perceptions of the usefulness of PN
and how it made them feel) and the effect PN has on
various psychosocial variables such as informed choice
and BSS knowledge [28–36]. If ESQs are not returned
within 2 weeks, a reminder ESQ with a freepost-return
envelope will be sent.
Additionally, at the end of the study, qualitative inter-
views will be conducted with the SSPs, to allow an
evaluation of the barriers and facilitators for implement-
ing PN at the organisational level, exploring how PN
affected SSP’s workload and processes in the wider
department.
Sample size
Currently, there is no directly comparable evidence to
estimate the number of people who will consent to take
part in this study. Because our sample is likely to consist
of people who support the BSS in principle, we have
used recruitment figures from the UK FS trial as a guide
to estimating our recruitment rate.
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South of Tyne Screening Centre will invite approxi-
mately 960 people for BSS at STDH during the recruit-
ment period. In the UK FS trial, 55 % of those initially
approached were interested in receiving a FS examin-
ation [37]. Given that people in this study will receive an
invitation for BSS regardless of their response to our
invitation, recruitment may be lower (i.e. 40 %; N = 384).
It is likely that uptake among this self-selected sample
would be higher than for the general population. On the
basis of the UK FS trial, we predict that about 70 % of
the sample would attend their original appointment as
part of the usual pathway. The remaining 30 % of con-
senting participants would fail to attend their appoint-
ment (N = 116) of whom we would allocate two thirds
(N = 77) to receive PN.
Using A’Hern single-stage design, with 20 % significance
level and 80 % power, at least 35 participants would need to
re-schedule and subsequently attend their appointment for
PN to be considered worthy of further investigation [24].
Outcome measures
The primary outcome measure of this study will be the
number of non-attenders in the PN group who are navi-
gated and then re-book and attend their new BSS
appointment.
Additional outcomes measures will include the following:
Barriers to BSS attendance: All PN sessions will be
audio recorded (with patient permission) and
transcribed. An analysis of the transcripts will aim to
highlight all the barriers to attendance described by
patients and the extent to which they are modifiable.
An evaluation of the PN process: Approximately seven
SSPs will be assigned to this study. SSPs will monitor
the number of contact attempts made and the duration
of telephone calls made within each navigation episode.
The audio recordings of the navigation calls will also be
analysed with regard to the SSPs adherence to the PN
Patient information sheet, consent 
form and non-participation postcard 
mailed out with Bowel Scope 
Screening pre-invitation letter
Return non-participation 
postcard
Return completed 
consent form
Do not respond to study 
invitation
Control
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and 
Attend
Do Not 
Confirm / 
Attend
Receive PN 
call but then                   
refuse or do 
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No 
PN call
needed
Missed
PN call
attempts
Receive    
PN call   
and then 
attend
4 weeks1 week
Confirm 
and 
Attend
Do Not 
Confirm / 
Attend
End of Study 
Questionnaire V1
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REMINDER           
ESQ V3
End of Study 
Questionnaire V3
2-3 weeks
REMINDER           
ESQ V4
End of Study 
Questionnaire V4
2-3 weeks
End of Study 
Questionnaire V2
2-3 weeks
REMINDER           
ESQ V1
REMINDER           
ESQ V2
PNRandomised
4 weeks
Fig. 3 Flowchart of study materials
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manual, the type of support given (e.g. practical and/or
emotional), and the action plans agreed with patients.
Exit interviews with SSPs will be conducted, audio
recorded and analysed with the aim of ascertaining
their views on the PN process. Exit interviews will
either be conducted face-to-face within the hospital
setting or over the telephone, whichever is most con-
venient for each SSP.
Patient-reported outcomes: Completed ESQs will be
analysed to ascertain the number of people making an
informed choice in both groups and, where relevant,
satisfaction with the BSS procedure and PN intervention.
Reasons for not participating in the study: A brief
freepost-return A5 postcard will be provided within the
study invitation envelope that will be sent alongside the
BSS pre-invitation letter. The postcard will give those
not wanting to take part in the study the option to
choose among reasons for non-response/refusal (e.g. ‘I
do not want to share my personal details with the re-
searchers’, ‘I did not think I will need any support’), with
responses considered in the development of the RCT.
Economic analysis: We will calculate the cost of
delivering the PN intervention, including SSP time, and
training. We will also plan the economic evaluation
that would accompany the full RCT.
Planned analyses
Primary analysis
The overall recruitment and uptake rates by trial arm
will be described; the study is not powered to make a
direct comparison between arms but will help inform
sample size requirements for a phase III trial.
Qualitative analysis
Transcripts of the PN telephone calls and interviews
with SSPs will be analysed separately and managed using
QSR International’s NVivo 10 Software. Framework ana-
lysis will be applied to the PN telephone call transcripts,
with aspects such as the barriers highlighted, advice
given, and outcomes achieved extracted for review [38].
SSP interviews will be analysed using thematic analysis
with an inductive approach as we aim to gain insight
into the views of SSPs with regard to the intervention’s
concept and design, and their experience of intervention
delivery [39]. One member of the research team will lead
the analysis with a further two research team members
involved in discussions to verify the results. A sub-
sample of anonymised transcripts will be read by our pa-
tient representative to check interpretations by the main
research team. The telephone transcripts will also be
matched to the corresponding SSP interview transcript to
give context to the interviews and triangulate the data.
Quantitative analysis
Data collected on the study database and from returned
non-participation postcards will be analysed and mainly re-
ported as descriptive data (e.g. attendance rates, time for re-
turn of ESQs, number of people selecting specific reasons
for non-study participation). The ESQ data will be analysed
using a mixture of descriptive and inferential statistics in-
cluding chi-square analysis and linear and logistic regres-
sion so that predictors of attendance and non-attendance
can be investigated, as can between group differences in
views, attitudes, knowledge and satisfaction with BSS. Re-
sults will be presented with a 95 % confidence interval.
Economic analysis
A detailed analysis of the cost of PN versus usual care
will be undertaken. First, the analysis will include the
costs of SSP training and time, plus other costs during
the navigation pathway. Second, we will calculate the
impact of PN on subsequent bowel cancer screening and
diagnosis. Health service contacts will be collected by
the UCL researchers during the study from patients, plus
the routinely recorded data within the BCSP, and priced
using national unit cost data. Third, we will undertake a
feasibility study for a full economic evaluation of PN ver-
sus usual care. The aim is to plan the economic evalu-
ation that would accompany the definitive RCT. We will
develop a plan to estimate the lifetime incremental cost
per quality-adjusted life year (QALY) gained of the inter-
vention in the definitive RCT. In the present study, we
will identify the following: (a) the main NHS/Personal
Social Services (PSS) cost components; (b) the resource
use and unit cost data required for each of these cost
components and how best to source these data; (c) po-
tential sources of health-related quality of life data suit-
able for estimating QALYs in this patient group and, if
primary data collection is required, how best to do this
using pre-existing instruments such as the EuroQol-5
Dimensions Scale (5 level; EQ-5D-5L) (Kind P: The
EuroQol instrument: an index of health-related quality
of life, unpublished); (d) the potential sources that could
be used to estimate residual life expectancy and other
long-term outcomes among patients; and (e) the non-
NHS/PSS impacts that are important to record (e.g. days
off work) and how best to obtain these.
Trial status
Data collection is ongoing but the randomisation ratio
has now been increased to 4:1 in favour of the interven-
tion, following lower than expected consenting rates
within the first 3 months of recruitment.
Discussion
BSS offers the unique benefit of reducing CRC incidence
as well as mortality, but this benefit can only be realised
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through uptake of the procedure. Within the first
14 months of the BSS programme’s launch, 21,187 invi-
tations were sent out to eligible people across six pilot
centres in England and the overall uptake was 43 % [8].
Although this was higher than expected in the early
stages of the programme’s national roll-out, a need to
proceed with interventions to boost uptake and reduce
socioeconomic inequalities was highlighted [8]. Within
the South of Tyne Screening Centre specifically, a below
average uptake of only 37 % was reported, promoting
itself as a key centre in which to base intervention
initiatives.
Incorporating PN within the NHS BCSP, and provid-
ing a more personal and interactive way of communicat-
ing information about BSS, seems likely to circumvent
many of the barriers associated with CRC screening. As
part of their role as patient navigator, SSPs will have the
opportunity to communicate the benefits of BSS more
effectively and help to manage the feelings and fears as-
sociated with cancer screening and diagnosis, alongside
access to care and other logistical issues. While naviga-
tion has been shown to work in the USA, its integration
into the UK system requires investigation not only from
a theoretical standpoint but also a practical one. This
study not only aims to assess the acceptability of PN but
also how it can be implemented within the system.
Potential limitations, challenges and risks
Unfortunately, the telephone numbers of people eligible
for BSS are not readily available within the programme
and are only provided to SSPs through the appointment
confirmation process. For this reason, and to adhere to
research ethical standards, we will have to obtain con-
sent to take part in this study and, as part of the consent
process, specifically request the provision of an individ-
ual’s telephone number(s). It is possible that the consent
process will represent a barrier and ultimately restrict
the intervention to more ‘activated’ individuals, thereby
introducing a selection bias. However, we have taken this
into consideration and have assumed a higher uptake
rate (70 %) within our sample compared to the general
population.
Furthermore, there is a risk that people will mistake
the consent for the study as confirmation of their future
attendance at a BSS appointment which could negatively
affect the BSS invitation process. As a result, we will
closely monitor the impact of the study invitations on
BSS uptake.
An additional limitation is that the PN training session
and related manual will be developed and delivered by
non-PN experts, which may lower the extent to which
SSPs accept and identify with the PN intervention and
their confidence to perform it.
Conclusion
The results of this feasibility study will be instrumental
in deciding whether a proposal will be made to conduct
a large-scale RCT of the PN intervention in the BSS
programme, in England. If PN was subsequently shown
to be cost-effective at increasing uptake of BSS, NHS
policies could be modified to implement PN as a stand-
ard service. Another important part of this feasibility
study will be to identify barriers associated with BSS.
Disseminating the findings from this study will therefore
facilitate the development of additional strategies to
increase uptake of BSS.
Additional file
Additional file 1: SPIRIT 2013 Checklist: Recommended items to address
in a clinical trial protocol and related documents. (DOC 120 KB)
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